Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab

KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux®) in metastatic colorectal cancer (mCRC). This study sought to determine if KRAS mutant CRC lines could be sensitized to cetuximab using dasatinib (BMS-354825, sprycel®) a potent, orally bioavailable inhibitor of several ty...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Dunn, Emily F., Iida, Mari, Myers, Rebecca A., Hintz, Kylee A., Campbell, David A., Armstrong, Eric A., Li, Chunrong, Wheeler, Deric L.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2010
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3025039/
https://ncbi.nlm.nih.gov/pubmed/20956938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2010.430
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items